Compromised liver function can pose serious risks in patients undergoing treatment for HER2+ advanced breast cancer, making early detection and proactive management essential. Stay ahead by learning effective strategies for monitoring liver health and optimizing patient outcomes with HER2-directed therapies. In the third Clinical Case Challenge in this series, evaluate your ability to identify and manage hepatotoxicity in patients receiving novel HER2-directed therapies. Compare your performance with peers on the leaderboard and gain real-time, evidence-based expert commentary from a leading breast oncologist.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/liver-disease-hepatotoxicity-considerations-patients-her2-plus-mbc
- Start Date: 2025-02-28 06:00:00
- End Date: 2025-02-28 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 31000.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 4714.29 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest